Novo Nordisk A/S Common Stock (NVO)

Operating Expenses

kr 34.33B

Quarterly · Period ending: · DKK

NVO logo

NVO Operating Expenses

Latest reportedkr 34.33B DKK
NVO Quarterly Operating Expenses · DKK (kr 985.86M → kr 34.33B)
High-resolution chart · PNG

NVO operating expenses history

Quarterly · DKK. Dates are reporting period ends; fiscal years can differ from calendar years.

Novo Nordisk A/S Common Stock Operating Expenses — Quarterly (DKK)
Period endingOperating Expenses (DKK)
34,327,000,000
23,607,000,000
32,260,000,000
33,390,000,000
30,562,000,000
26,406,000,000
35,922,000,000
26,181,000,000
31,852,000,000
23,587,000,000
29,083,000,000
22,105,000,000
22,556,000,000
20,178,000,000
22,743,000,000
18,182,000,000
16,805,000,000
15,967,000,000
18,458,000,000
14,314,000,000
12,715,000,000
13,011,000,000
15,341,000,000
12,964,000,000
11,396,000,000
12,187,000,000
15,112,000,000
12,283,000,000
11,735,000,000
10,320,000,000
14,296,000,000
11,534,000,000
10,851,000,000
10,285,000,000
13,245,000,000
10,298,000,000
10,843,000,000
10,711,000,000
13,448,000,000
11,131,000,000
10,917,000,000
10,669,000,000
13,143,000,000
10,965,000,000
10,718,000,000
7,469,000,000
11,429,000,000
10,254,000,000
9,225,000,000
8,844,000,000
10,944,000,000
8,994,000,000
9,189,000,000
8,812,000,000
10,237,000,000
8,496,000,000
8,391,000,000
7,963,000,000
8,917,000,000
7,671,000,000
7,637,000,000
7,158,000,000
8,695,000,000
7,524,000,000
7,384,000,000
6,602,000,000
7,208,000,000
6,018,000,000
6,301,000,000
6,180,000,000
6,746,128,000
5,316,000,000
5,710,857,000
5,372,000,000
7,262,844,200
5,306,670,000
5,396,334,000
5,167,987,000
5,796,450,000
4,740,900,000
4,845,208,000
4,654,049,000
4,965,549,000
4,125,062,000
3,729,597,000
3,666,784,000
3,936,690,000
3,560,712,000
3,339,233,000
3,184,129,000
5,431,789,000
5,076,691,000
4,875,292,000
4,771,662,000
6,682,043,000
6,445,668,000
5,278,480,000
6,020,344,000
6,503,165,000
6,652,112,000
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.